PD 32766
Alternative Names: 225Ac/64Cu-CA9; 225Ac/64Cu-CA9 - Peptidream; 64Cu-PD-32766; 64Cu-PD-32766 - PeptiDream; CAIX programme; PD-32766Latest Information Update: 10 Jun 2024
At a glance
- Originator PeptiDream
- Class Radiopharmaceuticals
- Mechanism of Action Carbonic anhydrase IX inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Renal cell carcinoma
Most Recent Events
- 04 Jun 2024 Clinical trials in Renal cell carcinoma (Metastatic disease, Locally recurrent) in Japan (unspecified route) (jRCTs031240046)
- 04 Dec 2023 Preclinical trials in Renal cell carcinoma in Japan (unspecified route) (PeptiDream pipeline, December 2023)
- 04 Dec 2023 PeptiDream plans a additional human imaging studies in 1H 2024